Home›Coccidioides Immitis Spherule-Derived Skin Test Antigen

Coccidioides Immitis Spherule-Derived Skin Test Antigen

Also known as: Spherusol

Skin Test Antigen

Route: Intradermal

Check Coccidioides Immitis Spherule-Derived Skin Test Antigen Interactions →

3 interactions on record⛔ Black Box Warning

Coccidioides Immitis Spherule-Derived Skin Test Antigen has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Acidifying Agents, Corticosteroids. Patients taking Coccidioides Immitis Spherule-Derived Skin Test Antigen should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 2

Moderate (2)

Coccidioides Immitis Spherule-Derived Skin Test Antigen + Acidifying Agents— Immunosuppressive agents may suppress the response to the skin test.
Coccidioides Immitis Spherule-Derived Skin Test Antigen + Corticosteroids— Corticosteroids may suppress the response to the skin test. Pharmacologic doses may suppress response after two weeks of…

Coccidioides Immitis Spherule-Derived Skin Test Antigen + Acidifying Agents🟡Moderate

Immunosuppressive agents may suppress the response to the skin test.

Coccidioides Immitis Spherule-Derived Skin Test Antigen + Corticosteroids🟡Moderate

Corticosteroids may suppress the response to the skin test. Pharmacologic doses may suppress response after two weeks of therapy through decreased monocytes and lymphocytes, particularly T-cells.

Coccidioides Immitis Spherule-Derived Skin Test Antigen + Azole Antifungalsℹ️Unknown

Concurrent treatment with antifungal medications may interfere with delayed-type hypersensitivity responses, though this interaction has not been formally evaluated.

⛔ FDA Black Box Warning

WARNING The expected response to Spherusol ® is a local area of inflammation at the site of the skin test. The reaction is usually dime to quarter size reaching maximum diameter between 24 and 48 hours. Larger accelerated reactions can occur, which may require treatment with local cold compresses and anti-inflammatory medication. ( 2.3 , 6.1 ) Systemic reactions can occur with skin test antigens and in certain individuals these reactions may be life-threatening or cause death. Emergency measures and personnel trained in their use should be immediately available. Patients should be observed for at least 20 minutes following the administration of a skin test. ( 6.2 ) Spherusol ® should never be given intravenously. ( 5 ) To report SUSPECTED ADVERSE REACTIONS, contact Nielsen BioSciences, Inc. at (855) 855-1212 or MEDWATCH, Food and Drug Administration (FDA), 5600 Fishers Lane, Rockville, MD 20852-9782. Telephone: (800) 332-1088 or www.vaers.hhs.gov . ( 6.2 ) WARNING See full prescribing information for complete boxed warning The expected response to Spherusol ® is a local area of inflammation at the site of the skin test. The reaction is usually dime to quarter size reaching maximum diameter between 24 and 48 hours. Larger accelerated reactions can occur, which may require treatment with local cold compresses and anti-inflammatory medication. ( 2.3 , 6.1 ) Systemic reactions can occur with skin test antigens and in certain individuals these reactions may be life-threatening or cause death. Emergency measures and personnel trained in their use should be immediately available. Patients should be observed for at least 20 minutes following the administration of a skin test. ( 5.3 , 6.2 ) Spherusol ® should never be given intravenously. ( 5 ) To report SUSPECTED ADVERSE REACTIONS, contact Nielsen BioSciences, Inc. at (855) 855-1212 or MEDWATCH, Food and Drug Administration (FDA), 5600 Fishers Lane, Rockville, MD 20852-9782. Telephone: (800) 332-1088 or www.vaers.hhs.gov .

Contraindications

4 CONTRAINDICATIONS A severe allergic reaction (e.g., anaphylaxis) to Spherusol ® , or any component of Spherusol ® or other coccidioidin products is a contraindication to administration. Severe allergic reaction (e.g., anaphylaxis) to Spherusol ® , or any component of Spherusol ® or other coccidioidin products. ( 4 )

Pregnancy & Breastfeeding

8.1 Pregnancy The safety and effectiveness of Spherusol ® in pregnant women have not been established. Pregnancy Category C Animal reproduction studies have not been conducted with Spherusol ® . It is also not known whether Spherusol ® can cause fetal harm when administered to a pregnant woman or affect reproduction capacity. Spherusol ® should be given to a pregnant woman only if clearly needed.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.